MX2023012901A - Compuestos heterocíclicos como agonistas del receptor de activacion expresado en las células mieloides 2 y métodos de uso. - Google Patents

Compuestos heterocíclicos como agonistas del receptor de activacion expresado en las células mieloides 2 y métodos de uso.

Info

Publication number
MX2023012901A
MX2023012901A MX2023012901A MX2023012901A MX2023012901A MX 2023012901 A MX2023012901 A MX 2023012901A MX 2023012901 A MX2023012901 A MX 2023012901A MX 2023012901 A MX2023012901 A MX 2023012901A MX 2023012901 A MX2023012901 A MX 2023012901A
Authority
MX
Mexico
Prior art keywords
myeloid cells
receptor expressed
agonists
methods
compounds
Prior art date
Application number
MX2023012901A
Other languages
English (en)
Inventor
Bhaumik Pandya
Alan Kaplan
John Mancuso
Maxence Bos
Jonathan B Houze
Ivan Franzoni
Original Assignee
Vigil Neuroscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vigil Neuroscience Inc filed Critical Vigil Neuroscience Inc
Publication of MX2023012901A publication Critical patent/MX2023012901A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente descripción proporciona compuestos de la Fórmula I, útiles para la activación del receptor de activación expresado en células mieloides 2 ("TREM2"). (VER FORMULA) esta descripción proporciona además composiciones farmacéuticas que comprenden los compuestos, usos de los compuestos y composiciones para el tratamiento de, por ejemplo, un trastorno neurodegenerativo; además, la descripción proporciona productos intermedios útiles en la síntesis de compuestos de Fórmula I.
MX2023012901A 2021-05-04 2022-05-04 Compuestos heterocíclicos como agonistas del receptor de activacion expresado en las células mieloides 2 y métodos de uso. MX2023012901A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163201531P 2021-05-04 2021-05-04
US202163263811P 2021-11-09 2021-11-09
PCT/US2022/072095 WO2022236272A2 (en) 2021-05-04 2022-05-04 Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use

Publications (1)

Publication Number Publication Date
MX2023012901A true MX2023012901A (es) 2024-01-22

Family

ID=83932995

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012901A MX2023012901A (es) 2021-05-04 2022-05-04 Compuestos heterocíclicos como agonistas del receptor de activacion expresado en las células mieloides 2 y métodos de uso.

Country Status (10)

Country Link
EP (1) EP4334295A2 (es)
JP (1) JP2024519497A (es)
KR (1) KR20240026911A (es)
AU (1) AU2022269034A1 (es)
BR (1) BR112023023008A2 (es)
CA (1) CA3219215A1 (es)
IL (1) IL308167A (es)
MX (1) MX2023012901A (es)
TW (1) TW202309029A (es)
WO (1) WO2022236272A2 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2940972A (en) * 1957-06-27 1960-06-14 Thomae Gmbh Dr K Tri-and tetra-substituted pteridine derivatives
US2963481A (en) * 1959-11-27 1960-12-06 Smith Kline French Lab 6-pteridinecarboxylic acid esters
KR101438245B1 (ko) * 2006-08-23 2014-09-04 쿠도스 파마슈티칼스 리미티드 Ｍｔｏｒ 억제제로서의 2-메틸모르폴린 피리도-, 피라조- 및 피리미도-피리미딘 유도체
BRPI0818426A2 (pt) * 2007-10-15 2017-06-13 Astrazeneca Ab produto de combinação, uso de um produto de combinação, e, método para tratar câncer
TW202208355A (zh) * 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法

Also Published As

Publication number Publication date
CA3219215A1 (en) 2022-11-10
EP4334295A2 (en) 2024-03-13
BR112023023008A2 (pt) 2024-02-15
TW202309029A (zh) 2023-03-01
IL308167A (en) 2023-12-01
JP2024519497A (ja) 2024-05-14
AU2022269034A1 (en) 2023-11-16
WO2022236272A3 (en) 2022-12-22
KR20240026911A (ko) 2024-02-29
WO2022236272A2 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
CR20220560A (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 y métodos de uso
MX2022013838A (es) Compuestos heterociclicos como agonistas del receptor de activacion expresado en las celulas mieloides 2 y metodos de uso.
US11052070B2 (en) Riluzole prodrugs and their use
IL177291A0 (en) Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
UA85576C2 (ru) Тетразольные соединения и их применение в качестве метаботропических антагонистов рецепторов глутамата
CR20220371A (es) Agonistas heterocíclicos de glp-1
ZA202306748B (en) Glp-1r receptor agonist compound and use thereof
MX2007008614A (es) Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r).
TW200732313A (en) Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
PL1725536T3 (pl) Pochodne imidazoliny mające czynność CB1-antagonistyczną
TW200716528A (en) Cyclopropanecarboxamide derivatives
MXPA05010824A (es) Compuestos biciclicos como antagonistas del receptor nr2b.
MEP6808A (xx) Priperidinoilpirodolini agonisti receptora menalokortina tipa 4
GB0517175D0 (en) Compounds
MX2008001606A (es) Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico.
MX2008002805A (es) Derivados de carboxamida como antagonistas del receptor muscarinico.
MXPA05007115A (es) Nuevos agonistas inversos del receptor cb 1.
GB0701366D0 (en) Novel pharmaceutical compositions
TW200740781A (en) Novel compounds
MX2022000550A (es) Imidazopirimidinas como inhibidores de eed y uso de estas.
TW200510378A (en) N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
TW200720262A (en) Novel compounds ii
JOP20220084A1 (ar) مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
JOP20220082A1 (ar) مشتقات 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4
MX2023012901A (es) Compuestos heterocíclicos como agonistas del receptor de activacion expresado en las células mieloides 2 y métodos de uso.